Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Neogen Corporation
NEOG
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $2.0B
$9.34
▲ +0.32%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$4.56 - $11.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 78.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Comprehensive product portfolio addressing multiple food and animal safety concerns
- Established relationships with major food processors, producers, and veterinary professionals globally
- Proprietary diagnostic technologies and rapid testing capabilities (AccuPoint Advanced)
- Regulatory expertise and compliance certifications across international markets
- Integrated business model serving interconnected food safety and animal health ecosystems
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Turning profitable
Increasing regulatory requirements and food safety standards worldwide
Value
Fairly valued vs Life Sciences Tools peers
Momentum
Stable
-1.1% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NEOG right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 8, 2026
APR 9, 2026
Reported EPS of $0.09 vs $0.04 consensus (+125.0% surprise). Revenue of $211.2M vs $204.5M expected (+3.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+125.0%
Next: Apr 8, 2026
Revenue trend · last 8Q
—
—
—
-3%
-5%
-4%
-3%
-4%
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
$236.8M
$217.0M
$231.3M
$221.0M
$225.5M
$209.2M
$224.7M
$211.2M
Margins · last 8Q
Gross
46.9%
Operating
-1.6%
Profit
-8.1%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · $10.00 · Jan 12, 2026